EGFR expression

Sorafenib is the first-line therapy for advanced hepatocellular carcinoma (HCC)...Silencing ST3GAL1 significantly reduced Siglec-7 ligand expression on liver cancer cells, enhancing their susceptibility to NK-mediated cytotoxicity and cetuximab-induced antibody-dependent cellular cytotoxicity (ADCC) in epidermal growth factor receptor (EGFR)-expressing tumor cells...Moreover, its elevated expression is associated with adverse clinical outcomes in HCC. Targeting ST3GAL1 may represent a promising strategy to enhance NK cell-mediated anti-tumor immunity in HCC.

Combined positivity offered superior correlation with lymph node metastasis (p<0.001) and advanced clinical stage versus individual markers. Integrated p53/Ki-67/EGFR assessment advances OSCC prognostication, warranting routine pathological use for enhanced clinical decision-making.

Overall, our results suggest that multiple pathways of EV biogenesis may operate in glioma cells resulting in formation of complex EV landscapes consisting of EGFR-positive and EGFR-negative EV subsets. This heterogeneity may have important implications for EV functions and EV-based diagnostics.

Clinically, multiplex immunofluorescence of patient tumors demonstrated strong co-expression of EGFR, LC3, and SLC16A3, which correlated with poor disease-free survival. Our study reveals a previously unrecognized EGF-secretory autophagy axis that orchestrates metabolic remodeling in TNBC and highlights the therapeutic potential of targeting the secretory autophagy- SLC16A3-lactate pathway to restrain metastasis.

Izalontamab brengitecan (Iza-bren; BL-B01D1) is a bispecific ADC targeting EGFR and HER3 that has demonstrated activity in other malignancies. Importantly, tumor tissue obtained at progression after BL-B01D1 treatment confirmed ABCG2 upregulation, validating a clinically relevant resistance mechanism. These findings support BL-B01D1 as a promising therapeutic strategy in mCRPC and nominate ABCG2 as a rational target for overcoming resistance.

P1, N=10, Recruiting, Jiyan Liu | Not yet recruiting --> Recruiting | Initiation date: Jul 2025 --> Feb 2026

P1/2, N=228, Not yet recruiting, Biotech Pharmaceutical Co., Ltd.

Additionally, new therapeutic interventions, such as microbiome-targeted therapies or probiotics, are suggested to enhance the efficacy of ICIs. By uniquely integrating clinical correlations with mechanistic insights on immune microenvironment, this may render pulmonary microbiota to be potential therapeutic strategies for future immunotherapy treatments.

After discontinuing the drug and giving continuous norepinephrine to increase BP, the patient's BP returned to stable. This case suggests that although nimotuzumab-related hypotension is mostly mild and reversible, BP monitoring should still be strengthened to maintain vigilance against severe hypotension and intervene promptly in clinical practice.

Systemic treatment with the EGFR-MMP-MP1 fusion significantly reduced tumor size in MDA-MB-468 xenograft models, confirming in vivo efficacy against cancer cells and acceptable systemic toxicity. We conclude that EGFR-MMP-MP1 peptides represent a novel cancer therapeutic for further development.

The faster mobility of mutation-activated ErbB2 contrasted with the EGF-induced slowing down of its lateral diffusion. In summary, single amino acid substitutions across ErbB2 domains may modulate receptor dynamics, organization, and responsiveness.

P2, N=20, Not yet recruiting, Fudan University